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Abstract 
 
Background:Total laryngectomy remains the treatment of choice for recurrent/persistent 
laryngeal squamous cell carcinoma(LSCC) after radiation(RT) or chemoradiation(CRT). 
However, despite attempts at aggressive surgical salvage, survival in this cohort remains 
suboptimal.    
Methods:A prospectively-maintained single-institution database was queried for patients 
undergoing total laryngectomy for recurrent/persistent LSCC after initial RT/CRT 
between 1998-2015(n=244).  Demographic, clinical, and survival data were abstracted.  
Kaplan Meier survival curves and hazard ratios(HR) were calculated.   
Results:Five-year overall survival was 49%.  Five-year disease-free survival was 58%.  
Independent predictors of overall survival included severe comorbidity[ACE-27 
scale](HR 3.76; 95% CI 1.56 – 9.06), and positive recurrent clinical nodes(HR 2.91; 95% 
CI 1.74 – 4.88).   
Conclusion:Severe comorbidity status is the strongest predictor of overall survival, 
suggesting that increased attention to mitigating competing risks to health is critical.  
These data may inform a risk prediction model to allow for focused shared decision-
making, preoperative health optimization and patient selection for adjuvant therapies. 
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Introduction:  
 
Advanced laryngeal squamous cell carcinoma (LSCC) remains a highly morbid and fatal 
disease despite aggressive interventions.  Mortality is high in this cohort: larynx cancer 
affects over 13,000 patients in the United States, with over 3,500 deaths annually[1]. The 
results of the VA Cooperative Studies Program Laryngeal Cancer Trial and subsequent 
studies demonstrated similar overall survival rates for organ preservation protocols 
involving radiation (RT) or chemoradiation (CRT) when compared to surgery, with the 
benefit of preserving the larynx in a large majority of patients[2-5]. As such, the use of RT 
or CRT has become the predominant initial intervention for patients with LSCC[6].   
However, the prognosis of recurrent and persistent LSCC is particularly dire.   
 
Notably, a significant subset of patients undergoing RT or CRT for LSCC will develop 
recurrent disease.  Five-year disease-free survival rates for advanced LSCC treated with 
organ preservation protocols ranges from 30-60% [3, 5, 7]; for most with 
recurrent/persistent disease, salvage laryngectomy is often the only remaining curative 
therapeutic modality.  Despite this, 5-year overall survival remains poor and is further 
compounded by a short disease-free interval [8]. The morbidity of salvage surgery in such 
patients is considerable; moreover, survival for patients with recurrent or persistent 
LSCC is poor, but incompletely characterized [9-11].  
 
To date, there have not been studies focused on assessing prognostic variables for 
patients considering salvage laryngectomy.  While overall survival and recurrence rates 
are well described for primary LSCC, there is a paucity of data assessing outcomes for 
patients undergoing salvage laryngectomy.  As organ-preservation protocols are 
increasingly being implemented as first-line therapy and failure drives poor survival, this 
patient population will be increasingly important to consider.   Likewise, given recent 
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increases in personalized medicine and immunotherapy approaches for advanced head 
and neck squamous cell carcinomas [12, 13], it is critical to identify predictors for LSCC 
patients that may benefit from the addition of neo/adjuvant therapy in conjunction with 
salvage surgery.   
 
We sought to identify preoperative predictors of survival for patients with recurrent or 
persistent LSCC in order to set patient expectations and address modifiable risk factors. 
Identification of predictors of survival may also identify patients who could benefit from 
novel therapeutic agents in a neo/adjuvant fashion. Herein, we examine a cohort of 
patients with recurrent or persistent LSCC after definitive RT/CRT that have undergone 
total laryngectomy in order to identify potential preoperative predictors of clinical 
outcomes. 
 
Materials and Methods:  
Patient Identification and Data Collection 
A prospectively-maintained single-institution epidemiology database of patients with 
head and neck cancer was queried for eligible patients.  University of Michigan 
Institutional Review Board approval was obtained for this study (HUM00081554).  
Inclusion criteria specified adult patients with a diagnosis of LSCC initially treated with 
RT/CRT between 1998-2015, who had a salvage laryngectomy for recurrent/persistent 
disease at the primary site (n=244).  Demographic, clinical, and survival data were 
abstracted (Table 1).  Death was verified via medical records and the social security 
death index.  Primary outcome measures were overall survival (OS; time from salvage 
laryngectomy to death from any cause), disease-specific survival (DSS; time from 
salvage laryngectomy to death from recurrent/persistent LSCC), and disease-free 
survival (DFS; time from salvage laryngectomy to LSCC recurrence).  Survival was 
described with Kaplan-Meier methodology.  We focused our analysis on survival 
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patterns during the first five years after salvage surgery.  For comorbidities, the ACE-27 
index was used as previously described [14], with comorbidity status classified as none, 
mild, moderate, and severe.   
 
Preoperative data (Table 1) included patient demographics, smoking history (defined as 
current, former: quit over 1 year ago, or never), comorbidity status (ACE-27 scale), initial 
cancer characteristics, initial cancer treatment, and recurrent cancer clinical 
characteristics.  
 
Statistical Analysis 
We aimed to identify factors at the time of the preoperative evaluation, as this would be 
a key timepoint in which to discuss patient care options and prognosis.  Thus, we 
included variables available to clinicians at the preoperative appointment for 
recurrent/persistent LSCC.  We first calculated summary statistics to describe the 
analytical sample of N=244 patients with recurrent laryngeal cancer.  The Kaplan-Meier 
method was used to estimate survival curves for OS, DFS, and DSS. We then estimated 
the predicted state probabilities (alive, died from cancer, died from other causes) over 
time broken down by comorbidity level.  The probability of death from any cause was 
estimated using the Kaplan-Meier method, and the probability of death specifically from 
other causes was estimated using Cumulative Incidence, which accounts for the 
competing risks between death from other causes and death from cancer.  To identify 
additional preoperative factors associated with OS, DSS, and DFS, we fit a multivariable 
Cox proportional hazards regression model for each outcome.  Due to the large number 
of predictors, we used forward selection to identify the most important covariates for 
each model.  All analyses were performed using R version 3.3.0 (Vienna, Austria).  
 
Results:   
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30-day Mortality after Laryngectomy for Recurrent/Persistent LSCC 
The 30-day mortality for the entire cohort was 5% (13/244).   Cause of death in this 
cohort included cardiopulmonary arrest (3), carotid blowout (2), metastatic disease (2), 
stroke (1), bowel ischemia (1), pulmonary embolus (1), respiratory failure (1), infection 
(1), and unknown, not larynx cancer (1).  To understand the association between 
common perioperative morbidity and 30-day mortality, we compared fistula rate, return 
to the operating room for management of fistula/wound issues, and ACE-27 comorbidity 
status.  Our fistula rate was 34% (84/244; Table 2).  Our operative takeback rate was 
12% (30/244).  There was no association with the development of a fistula or return to 
the operating room and 30-day mortality.  There was an increasing and significantly 
worsened 30-day mortality for patients with mild/moderate and severe comorbidity 
status.   
 
Survival Analysis after Laryngectomy for Recurrent/Persistent LSCC 
In Kaplan Meier analysis, the estimated five-year OS was 49% within the entire cohort 
(95% confidence interval [CI] 42-56 %; Figure 1A).  Five-year DSS for the entire cohort 
was 68% (95% CI 61-75%; Figure 1B).  Five-year DFS for the cohort was 59% (95% CI 
52-67%; Figure 1C).  We next stratified the cohort by type of recurrence (locoregional 
versus distant).  In Kaplan Meier analysis, the estimated five-year locoregional DFS was 
71% (95% CI: 65% - 78%).  Five-year distant DFS was 78% (95% CI 71% - 85%). 
 
Multivariable Modeling of Preoperative Predictors of Survival 
We performed multivariable analysis in order to predict variables contributing to OS, 
DSS, and DFS.  Using a forward step model, we included demographic (gender, 
ethnicity, ACE-27 comorbidity status, tobacco use), initial tumor characteristic (age at 
initial tumor, initial site, initial cT classification, initial cN classification, initial overall 
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stage, initial treatment, initial treatment location), and recurrent tumor characteristic (age 
at recurrence, time to recurrence, recurrent site, recurrent cT classification, recurrent cN 
classification, recurrent overall stage; Table 1) variables.  In multivariable analysis, 
significant preoperative predictors of OS (Table 3) included severe comorbidity [ACE-27 
scale] (HR 3.76; 95% CI 1.56 – 9.06), recurrent clinical node positive status (HR 2.91; 
95% CI 1.74 – 4.88), and initial overall stage greater than I.  For DSS, predictors 
included recurrent clinical node positive status (HR 3.95; 95% CI 2.16 – 7.22), and initial 
overall stage greater than I.  Multivariable independent predictors of DFS (Table 3) 
included recurrent clinical node positive status (HR 3.26; 95% CI 1.83 – 5.78), and initial 
overall stage greater than I. 
 
 
To better assess the preoperative effect size of medical comorbidities on overall survival, 
we further stratified causes of death between cancer and non-cancer (namely, 
comorbidity) causes over time (Figure 2A-C).  Non-cancer causes of death contributed 
to significant decrease overall survival over a 5-year period in our overall cohort.  This 
was particularly evident in patients with moderate or severe comorbidities (Figure 2B), 
more than those with mild comorbidities (Figure 2A).  In analysis of rate of cancer 
versus non-cancer causes of death, for patients with moderate or severe comorbidities, 
non-cancer causes of death (i.e. comorbid conditions) was a greater cause of death than 
cancer-related causes through 30 months after salvage laryngectomy (Figure 2C).  
From 30 months to 5 years, patients with moderate or severe comorbidity status had an 
equal probability of dying from their comorbidities as their LSCC.  Cause of death for 
patients with no or mild comorbidity status is more likely to be due to a recurrence of 
disease. 
 
Discussion:  
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The prognosis after laryngectomy for recurrent/persistent LSCC remains guarded; we 
observed a 5-year OS probability of 49%.  Severe comorbidity status is the strongest 
independent predictor thereof, suggesting that careful preoperative discussions and 
increased attention to mitigating competing risks to health is critical in this population.  
Overall, in our cohort, we found that the strongest independent predictors included 
severe comorbidity and recurrent clinical node positive status for overall survival, and 
clinical node positive status for disease-free survival.  These data may allow for focused 
shared decision-making between patient and physician, and patient selection for 
potential adjuvant therapies. 
 
To date, there have been no multivariable analyses for prognostic factors for patients 
undergoing salvage laryngectomy.  For patients and physicians alike, identification of 
patients who may have poor predicted survival after salvage laryngectomy will be 
important to guide physician-patient discussions on goals of care, expectations and 
follow-up, and to consider for potential adjuvant or investigational treatment. 
 
Increasingly, management of comorbidities and chronic care are becoming key issues in 
the survivorship phase of head and neck cancer management [15].  Our data support that 
increased comorbidities have a significant effect on overall survival in patients 
undergoing salvage laryngectomy. Thus, strong consideration of patients’ competing 
risks of mortality in the preoperative setting may frame a realistic discussion on overall 
survival.  Additionally, there may be a role for active interventions to modify the life-
limiting impact of specific comorbidities (e.g. medications for depression or hypertension, 
treatment of cardiovascular and pulmonary disease, counseling on alcohol or 
preoperative smoking cessation).  Common modifiable risk factors included in the ACE-
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27 score include poorly controlled diabetes, hypertension, depression, obesity, and 
alcohol abuse.  
 
Interestingly, smoking status did not demonstrate significance on multivariable analysis.  
We postulate that the extensive smoking history of our patients with cumulative effects of 
smoking and almost universal smoking cessation after laryngectomy may explain any 
lack of effect on current smoking status on survival.  Additionally, the effects of smoking 
may be best reflected on the severity of comorbidities collected by ACE-27 
(cardiovascular, respiratory, neurologic disease, and malignancy), thus making ACE-27 
comorbidity status a more comprehensive factor in accounting for the effects of smoking 
on a patient’s survival.  Similarly, we did not see significance of clinical T classification 
on multivariable analysis.  Although advanced clinical T classification was associated 
with a worse outcome on univariable analysis, it was also correlated with clinical nodal 
positivity.  We postulate that this correlation and other variables (initial tumor factors, 
time to recurrence factors), may account for the lack of effect in multivariable analysis. 
 
Our analysis did not show any survival difference between initial treatment between 
initial RT or CRT at our institution versus outside hospitals.  In regards to outside 
hospital treatment, the University of Michigan collaborates closely with local hospitals in 
regards to radiation planning, in many cases assisting in the radiation fields to be 
implemented.  In addition, patient’s treated at the University of Michigan were more like 
to have supraglottic cancers (62% UM vs 36% OSH) and advanced stage cancers (57% 
UM vs 29% OSH), which may explain the lack of significance.   
 
Counseling and surgical decision-making when facing salvage surgery should 
emphasize the significant effect of comorbidities on survival, as well as the suboptimal 
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observed survival within this cohort.  Furthermore, counseling in regards to optimizing 
modifiable comorbidities (e.g. improved control of hypertension or COPD), may have 
valuable effects in a patient’s estimated 5-year survival.  Honest discussions about 
patient expectations and outcomes may guide further treatment plans.  Our data 
demonstrates increasingly worsening 30-day perioperative mortality with increasing 
comorbidity status, suggesting a need for careful preoperative patient stratification, risk 
reduction of modifiable comorbidity factors, and counseling on perioperative 
complications and survival.   
 
Despite our study’s strength as the largest cohort of patients with recurrent/persistent 
LSCC undergoing salvage laryngectomy, it does have limitations.  Initial tumor staging 
and treatment data was limited in some instances due to limited outside hospital records.  
The majority of our patients have their outside records sent to our institution, and staging 
reviewed at our tumor board, but in some cases this could be suboptimal.  However, this 
is a common clinical scenario for patients presenting with recurrent or persistent LSCC 
to tertiary cancer centers.  The vast majority of our patients had neck dissections, as this 
is standard practice amongst most of the surgeons in our institution (n = 225/244); no 
survival difference was seen with the performance of neck dissection.  The importance 
of neck dissection with salvage laryngectomy remains debated [16], and some institutions 
do not perform neck dissections regularly.  Further multi-institutional investigation by 
accruing survival data from patients with and without neck dissection may provide 
definitive data on this topic.   
 
Patients undergoing salvage laryngectomy have a guarded prognosis.  By stratifying 
based upon preoperative risk factors, we are able to define which subset of patients may 
have better or worse predicted outcomes.  This information may be crucial to guide 
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preoperative discussions on goals of care and consideration of adjuvant treatment 
modalities.  As cancer care increasingly implements genetic biomarkers and targeted 
therapies, we must continually consider additional methodologies for risk stratification.  
Further validation of these predictive variables across additional cohorts will be 
invaluable to further refine management algorithms. 
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Figure 1. 5-year Kaplan Meier Survival Curves .  5-year survival patterns demonstrate 
an overall survival of 49% (A; 95% CI 42-56 %), a disease-specific survival of 
68% (B; 95% CI 61-75%), and disease-free survival of 59% (C; 95% CI 52-67%). 
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Figure 2. Contribution of Comorbidity Status to Overall Survival.  Cumulative 
proportion of subjects who died from cancer and non-cancer causes over 5 years (A).  
Patients with moderate or severe comorbidities are more likely to die from their 
comorbidities and other causes than cancer through 30 months (B, C).  The y-axis is the 
ratio of probability of dying from LSCC versus non-cancer causes.  Ratio of probability at 
1 (horizontal line) denotes an equal probability of dying from non-cancer causes as dying 
from cancer.  Lines below 1 suggest a greater risk of dying from non-cancer causes and 
lines above 1 denote greater risk of dying from LSCC (C).   
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Table 1. Cohort Characteristics (n=244) 
 N (%)  
Or Mean (SD) 
Missing, N (%) 
Patient Characteristics 
Gender 
    Male 
    Female 
Ethnicity 
    White 
    Black/Other/Unknown 
Comorbidities 
    None 
    Mild 
    Moderate 
    Severe 
Tobacco Use 
    Current 
    Former 
    Never 
 
 
208 (85.2) 
36 (14.7) 
 
223 (91.3) 
21 (8.6) 
 
49 (20.0) 
129 (52.8) 
51 (20.9) 
15 (6.1) 
 
92 (37.7) 
146 (59.8) 
6 (2.4) 
 
 
0 (0) 
 
 
0 (0) 
 
 
0 (0) 
 
 
 
 
0 (0) 
Initial Cancer  
Age at Initial Tumor 
Initial Site 
    Glottis 
    Supraglottis 
    Subglottis 
Initial cT Classification 
    cT1 
    cT2 
    cT3 
    cT4 
Initial cN Classification 
    cN0 
    cN+ 
Initial Stage 
    I 
    II 
    III 
    IV 
Initial Treatment 
    RT 
    CRT 
Initial Treatment Site 
    OSH 
    UM 
 
59.2 (10.1) 
 
143 (58.6) 
98 (40.1) 
0 (0) 
 
63 (25.8) 
71 (29.0) 
65 (26.6) 
28 (11.4) 
 
188 (77.0) 
40 (16.3) 
 
63 (25.8) 
62 (25.4) 
63 (25.8) 
39 (15.9) 
 
139 (56.9) 
105 (43.0) 
 
192 (78.6) 
52 (21.3) 
 
1 (0.4) 
 
3 (1.2) 
 
 
 
17 (6.9) 
 
 
 
 
16 (6.5) 
 
 
17 (6.9) 
 
 
 
 
0 (0) 
 
 
0 (0) 
Recurrent Cancer 
Age at Recurrence (yrs) 
Time to Recurrence (mo) 
Time to Recurrence < 2yr 
    Yes 
    No 
Recurrent Site 
 
61.2 (10.0) 
21.4 (30.2) 
 
126 (51.6) 
118 (48.4) 
 
 
0 (0) 
0 (0) 
 
0 (0) 
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    Supraglottis 
Recurrent cT Classification 
    cT1 
    cT2 
    cT3 
    cT4 
Recurrent cN Classification 
    cN0 
    cN+ 
Recurrent cStage 
    I 
    II 
    III 
    IV 
136 (55.7) 
108 (44.2) 
 
14 (5.7) 
97 (39.7) 
65 (26.6) 
68 (27.8) 
 
215 (88.1) 
29 (11.8) 
 
13 (5.3) 
93 (38.1) 
62 (25.4) 
76 (31.1) 
0 (0) 
 
 
0 (0) 
 
 
 
 
0 (0) 
 
 
0 (0) 
*Percentages calculated including the missing values where applicable.  Smoking status is 
defined as current (smoking within one year prior to surgery), or former (quit greater than one 
year prior to surgery). 
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Table 2.  Perioperative Complications in Patients Undergoing Surgery for 
Recurrent/Persistent LSCC. 
Comorbidity 
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
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Table 3. Multivariable Preoperative Predictors of Survival for Recurrent/Persistent LSCC.   
Characteristic OS  
HR (95% CI) 
DSS 
HR (95% CI) 
DFS 
HR (95% CI) 
Recurrent cN+ 
    No (ref) 
    Yes 
 
-- 
2.91 (1.74 – 4.88) 
 
-- 
3.95 (2.16 – 7.22) 
 
-- 
3.26 (1.83 – 5.78) 
Initial Stage 
    I (ref) 
    II 
    III 
    IV 
 
-- 
2.96 (1.59 – 5.51) 
3.40 (1.82 – 6.34) 
1.73 (0.81 – 3.66) 
 
-- 
2.62 (1.15 – 5.98) 
2.13 (0.82 – 5.53) 
0.99 (0.31 – 3.15) 
 
-- 
2.36 (1.12 – 4.97) 
3.14 (1.54 – 6.39) 
1.71 (0.73 – 4.00) 
Comorbidities 
    None (ref) 
    Mild/Moderate 
    Severe 
 
-- 
1.43 (0.86 – 2.38) 
3.76 (1.56 – 9.06) 
 
-- 
-- 
-- 
 
-- 
-- 
-- 
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